Lyon (France), June 14, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells, today announces that the Commercial Court of Lyon rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.
Erytech welcomes the interim order issued today by the President of the Commercial Court of Lyon. The latter rejected the attempt by Akkadian Partners to obtain the postponement of the vote on the merger. Consequently, Erytech shareholders will be able to validly vote on the merger on June 23, 2023.